Sterol 14-Demethylase Inhibitors for Trypanosoma cruzi Infections
- 1 January 2008
- book chapter
- Published by Springer Nature
- Vol. 625, 61-80
Abstract
Chagas disease is caused by infection with the protozoan pathogen, Trypanosoma cruzi. The only approved therapeutics for treating Chagas disease are two nitroheterocydic compounds (benznidazole and nifurtimox) that are suboptimal due to poor curative activity for chronic Chagas disease and high rates of adverse drug reactions. Sterol 14-demethylase inhibitors include azole antifungal drugs such as ketoconazole, fluconazole, itraconazole, and others. The first reports of potent activity of azole antifungal drugs against Trypanosoma cruzi came out about 25 years ago. Since then, a sizeable literature has accumulated on this topic. Newer triazole compounds such as posaconazole and D0870 have been shown to be effective at curing mice with chronic Trypanosoma cruzi infection. Small clinical studies with ketoconazole or itraconazole in humans with chronic Chagas disease have not demonstrated significant curative activity. However, there is good reason for optimism that newer compounds with greater potency and improved pharmacokinetic properties might be more efficacious. Data have been published demonstrating synergistic activity of azole drugs with various other compounds, indicating that combination chemotherapy may be an effective strategy as this field moves ahead. In light of the near absence of adequate therapeutics for curing patients with chronic Chagas disease, additional effort to develop better drugs needs to be a priority.Keywords
This publication has 50 references indexed in Scilit:
- The Protein Farnesyltransferase Inhibitor Tipifarnib as a New Lead for the Development of Drugs against Chagas DiseaseJournal of Medicinal Chemistry, 2005
- Comparative Efficacies of TAK-187, a Long-Lasting Ergosterol Biosynthesis Inhibitor, and Benznidazole in Preventing Cardiac Damage in a Murine Model of Chagas' DiseaseAntimicrobial Agents and Chemotherapy, 2005
- Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypesJournal of Antimicrobial Chemotherapy, 2004
- Cloning and analysis of Trypanosoma cruzi lanosterol 14α-demethylaseMolecular and Biochemical Parasitology, 2003
- Selective inhibition of mammalian lanosterol 14.alpha.-demethylase: a possible strategy for cholesterol loweringJournal of Medicinal Chemistry, 1993
- An experimental and clinical assay with ketoconazole in the treatment of Chagas diseaseMemórias do Instituto Oswaldo Cruz, 1993
- Avaliação da atividade terapêutica do itraconazol nas infecções crônicas, experimental e humana, pelo Trypanosoma cruziRevista do Instituto de Medicina Tropical de São Paulo, 1992
- The activity of ketoconazole and other azoles against Trypanosoma cruzi: biochemistry and chemotherapeutic action in vitroMolecular and Biochemical Parasitology, 1989
- Effects of ketoconazole on sterol biosynthesis by Trypanosomacruzi epimastigotesBiochemical and Biophysical Research Communications, 1986
- Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruziMolecular and Biochemical Parasitology, 1981